[company_age]2.0[/company_age][employees]2-10 employees[/employees][funding]Grant[/funding][description]Genewity B.V. is a young, innovative biotech company based in Leiden, Netherlands, specializing in cell and gene therapies. Founded by a team with a proven track record in the field, including the first multi-centric clinical trial for gene therapy in the EU (the RAG1 SCID trial), Genewity focuses on bringing groundbreaking therapies to market. Their current focus is on developing a novel therapy for generating autologous thymus tissue, a potentially revolutionary advancement in the field. This therapy aims to address immune disorders by regenerating the thymus gland, which plays a crucial role in the development and maturation of T cells, essential components of the immune system. Genewity's approach involves generating functional thymus tissue from a patient's own cells, potentially offering a personalized and effective treatment option. The company's close collaboration with the Leiden University Medical Center (LUMC) provides access to expertise and resources, further strengthening its position in the field. Genewity's commitment to innovation and its focus on a unique and potentially transformative therapy set it apart from other companies in the cell and gene therapy space.[/description][ps]Cell and gene therapies, specifically focusing on developing a novel therapy for generating autologous thymus tissue to treat immune disorders.[/ps]